Tag - RCEL

Avita Medical

BTIG starts Avita Medical at buy; PT $10

BTIG launched coverage of Avita Medical (NASDAQ:RCEL) with a “buy” rating and $10 price target. The stock closed at $8.32 on March 2. Avita’s RECELL system produces a suspension of spray-on-skin cells using a small...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.